Jan 07th 2013 - Edison Investment Research today published a report on OvaScience entitled "On Fertile Ground". In summary, the report says:
OvaScience is developing novel treatments for female infertility. The company’s near-term investment case effectively rests on the successful development and commercialisation of its lead product, AUGMENT, to improve the success rate of in vitro fertilisation (IVF). If study results are positive and AUGMENT retains its lower-risk regulatory status, we project peak US sales of $160m/year. The technology underpinning AUGMENT and OvaTure (preclinical) is based on the landmark scientific discovery of egg-producing stem cells (egg precursor cells, EggPC) in human ovaries.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »